Abstract: A pharmaceutical composition for treating diseases related to inflammation or injury such as ARDS, comprising: (a) an active material derived from human somatic cells, the active ingredient being an extracellular vesicle produced by human somatic cells; and (b) a pharmaceutically acceptable carrier. The somatic cells are selected from human tissue, bone marrow and/or blood-derived stem cells, etc. The dosage form of the pharmaceutical composition is selected from an atomized inhalation agent, eye drops and nasal drops. The pharmaceutical composition has storage stability and high dispersibility superior to those of a living cell formulation. A method for preparing an extracellular vesicle, comprising steps of culturing human somatic cells, removing cells from a culture system, mixing a culture solution with polyethylene glycol to form an extracellular vesicle modified by PEG, centrifuging, resuspending, etc.

Abstract: A composition for treating articular cartilage defects, and a manufacturing method, and a kit thereof, the composition comprising: a therapeutically effective amount of fat-derived mesenchymal progenitor cells, serum albumin solution, and sodium hyaluronate, Above 95% of the fat-derived mesenchymal progenitor cells have the surface antigen CD90, CD73, CD29, and CD49d, and express cytokines selected from TGF-?1, HGF, and VEGF. The composition has the effect of treating articular cartilage defects.